Open AccessReal-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review
Author(s) -
Francesco Passamonti,
Florian H. Heidel,
Rohan C. Parikh,
Mayank Ajmera,
Derek Tang,
Jose Alberto Nadal,
Keith L. Davis,
Pranav Abraham
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1358
Subject(s) - ruxolitinib , myelofibrosis , medicine , medical record , overall survival , surgery , pediatrics , bone marrow
Aim: To assess real-world ruxolitinib treatment patterns and outcomes in patients diagnosed with primary or secondary myelofibrosis. Materials & methods: Patient medical records were reviewed in six countries. Results: Eligible patients (n = 469) had a mean age of 63.5 years, and most were male (66.5%) with primary myelofibrosis (78.5%). Median duration of ruxolitinib treatment was 13.1 months; 40% of patients initiated treatment at the recommended dose. The Kaplan–Meier estimate of median survival from ruxolitinib initiation was 44.4 months (95% CI, 38.8–50.2 months). Approximately one quarter (23%) of patients continued ruxolitinib after progression. Conclusion: These results suggest an unmet need for more effective treatments for patients with myelofibrosis who failed ruxolitinib.